908 Devices Inc. (MASS) SEC Filings & Earnings Calls
EquiReason read 11 908 Devices Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-11 — Revenue up 23% YoY, adjusted EBITDA loss halved, raised low end of FY revenue guidance..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 474.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
11 Aug 20268-K · 2.02Revenue up 23% YoY, adjusted EBITDA loss halved, raised low end of FY revenue guidance.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $16M | +23% y/y |
| Recurring revenue · Q2-2026 | $5M | |
| GAAP gross margin · Q2-2026 | 52.0% | |
| Adjusted gross margin · Q2-2026 | 57.0% | |
| Net loss from continuing operations · Q2-2026 | $-12M | -8% y/y |
| Adjusted EBITDA loss · Q2-2026 | $-2M | -51% y/y |
| Cash, cash equivalents and marketable securities · 2026-06-30 | $102M | |
| Installed base · 2026-06-30 | 4,101 | +23% y/y |
| Devices placed in quarter · Q2-2026 | 198 |
Guidance
FY26 revenue raised to $68.0-70.0M from $67.0-70.0M; representing 21% to 25% year-over-year growth
Raised low end of FY revenue guidance, strong demand and margin improvement, large order win post-quarter.
Risks flagged
Still loss-making, though narrowing
“Net loss from continuing operations was $11.9 million” · word for word
11 Aug 202610-Q908 Devices reported Q2 2026 results with strong product revenue growth and margin expansion, but continued net losses and a decline in service revenue due to a defense customer funding pause.earningsopen
Figures in the filing · each found in the filing text
| Revenue · H1-2026 | $29M | +19% y/y |
| Net Income (Loss) from Continuing Operations · H1-2026 | $-24M | |
| Operating Cash Flow · H1-2026 | $4M | |
| Handheld Product Placements · H1-2026 | 365 | +14% y/y |
| Cumulative Handheld Product Placements · 2026-06-30 | 4,101 | +23% y/y |
| Cash, Cash Equivalents and Marketable Securities · 2026-06-30 | $102M |
Risks flagged
Customer Concentration
“Two customers represented 13% and 9% of total revenue, respectively, for the three months ended June 30, 2026.”
Dependence on Government Funding
“Service and contract revenue decreased by $0.4 million, or 10%, for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease was primarily related to a $0.9 million decrease in mass spec service revenue, driven by a $0.7 million decrease in extended service contracts for MX908 devices mainly related to a funding-re” · word for word
Contingent Consideration Volatility
“The change in fair value of contingent consideration was $6.4 million for the three months ended June 30, 2026.” · word for word
Accumulated Deficit
“As of June 30, 2026, we had an accumulated deficit of $247.2 million.” · word for word
8 Jul 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Dilution from earnout issuance; potential further dilution if additional contingent shares are issued.
“contingent right to receive up to an aggregate of 4,000,000 shares ... revenue ... met or exceeded the threshold of $37 million”
6 May 202610-QRevenue $13M (+14% y/y); Net Income $-12M; Operating Cash Flow $1Mopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $13M | +14% y/y |
| Net Income · Q1-2026 | $-12M | |
| Operating Cash Flow · Q1-2026 | $1M | |
| Product Revenue · Q1-2026 | $11M | +26% y/y |
| Recurring Revenue · Q1-2026 | $4M | -7% y/y |
| Product Gross Margin · Q1-2026 | 52.0% | |
| Handheld Product Placements · Q1-2026 | 167 | +6% y/y |
| Cumulative Handheld Placements · 2026-03-31 | 3,903 | +23% y/y |
| Cash and Marketable Securities · 2026-03-31 | $112M |
Risks flagged
Customer Concentration in Government
“Device orders from a government customer are typically large orders and can be impacted by the timing of their capital budgets.” · word for word
Funding Pause by Defense Customer
“a funding-related pause in service coverage by a United States defense customer which began to impact our service revenues in the fourth quarter of 2025.” · word for word
Contingent Consideration Volatility
“The increase in fair value was primarily due to the increase in the Company's publicly quoted share price during the three months ended March 31, 2026” · word for word
Accumulated Deficit
“As of March 31, 2026, we had an accumulated deficit of $235.3 million.” · word for word
6 May 20268-K · 1.01, 2.01, 2.02, 3.02, 7.01908 Devices acquired NIRLAB SA for $15M headline (cash+stock) plus up to $8M earn-out; NIR spectroscopy for material ID.acquisitionopen
Risks flagged
Integration risk from acquisition; earnout may cause further dilution.
“contingent earn-out consideration of up to $8,000,000 ... payable solely in Company Shares”
29 Apr 2026DEF 14AAnnual proxy statement filed; no material event disclosed.open
Figures in the filing · each found in the filing text
| Net Income (Loss) · FY2025 | $19M | |
| Net Income (Loss) · FY2024 | $-72M | |
| Total Stockholder Return (TSR) · FY2025 | $46.79 | |
| Total Stockholder Return (TSR) · FY2024 | $19.61 |
9 Mar 202610-KRevenue $56M (+18% y/y); Net loss from continuing operations $-33M (+37% y/y); Accumulated deficit $223Mopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $56M | +18% y/y |
| Net loss from continuing operations · FY2025 | $-33M | +37% y/y |
| Accumulated deficit · FY2025 | $223M |
Risks flagged
Continued operating losses and need for additional capital
“Since our inception, we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend on the successful further development and commercialization of our products.” · word for word
Macroeconomic headwinds: inflation, interest rates, tariffs
“General inflation in the United States, Europe, the Middle East and other geographies has recently been at levels not experienced in recent decades, which has led to higher prices for our raw materials and other inputs, as well as higher salaries and travel expenses, which could continue to negatively impact our business by increasing our cost of sales and o” · word for word
3 Mar 20268-K · 2.02Revenue $17M (+21% y/y); Revenue $56M (+18% y/y); Recurring revenue $20M (+22% y/y); Guidance: FY2026 revenue guidance $64.5M-$67.5M (15-20% growth)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $17M | +21% y/y |
| Revenue · FY2025 | $56M | +18% y/y |
| Recurring revenue · FY2025 | $20M | +22% y/y |
| Gross margin · Q4-2025 | 53.0% | |
| Adjusted gross margin · Q4-2025 | 57.0% | |
| Net income from continuing operations · Q4-2025 | $4M | |
| Adjusted EBITDA · Q4-2025 | $700000.00 | |
| Cash, cash equivalents and marketable securities · Q4-2025 | $113M | |
| Installed base · Q4-2025 | 3,736 | +24% y/y |
Guidance
FY2026 revenue guidance $64.5M-$67.5M (15-20% growth)
Provided FY2026 revenue guidance of $64.5M-$67.5M (15-20% growth), implying continued acceleration; Q4 2025 achieved positive adjusted EBITDA milestone; strong margin expansion.
Risks flagged
Dependence on U.S. federal and defense contracts; timing of large awards may cause quarterly volatility.
“Revenue growth driven by FTIR product revenue; OEM and funded partnership revenue relatively small.”
Divestiture of bioprocessing portfolio in March 2025; results for continuing operations only.
“In light of the divestiture of the bioprocessing product portfolio in March 2025, all financial results discussed in this release for current and prior periods are for continuing operations only.” · word for word
20 Jan 20268-K · 2.02Revenue $17M (+20% y/y); Revenue $56M (+17% y/y); Guidance: FY2025 revenue at high end of guidance (~$56M)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $17M | +20% y/y |
| Revenue · FY2025 | $56M | +17% y/y |
Guidance
FY2025 revenue at high end of guidance (~$56M)
Preliminary FY2025 revenue at high end of guidance; achieved positive adjusted EBITDA in Q4; strong macro trends support future growth.
Risks flagged
Preliminary results subject to audit adjustments; final results may differ.
“This financial information does not represent a comprehensive statement of the Company’s financial results... remains subject to the completion of financial closing procedures and internal reviews.” · word for word
10 Nov 202510-Q908 Devices reported Q3 2025 results: total revenue $14.0M (flat YoY), product gross margin declined, but service margin improved and handheld placements grew 33% YTD.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · 9M-2025 | $39M | +16% y/y |
| Net loss from continuing operations · 9M-2025 | $-38M | |
| Product revenue · 9M-2025 | $29M | +16% y/y |
| Service and contract revenue · 9M-2025 | $10M | +17% y/y |
| Product gross profit margin · 9M-2025 | 47.0% | |
| Service gross profit margin · 9M-2025 | 57.0% | |
| Handheld product placements · 9M-2025 | 497 | +33% y/y |
| Cumulative handheld placements · Q3-2025 | 3,512 | +26% y/y |
| Cash, cash equivalents and marketable securities · Q3-2025 | $112M | |
| Operating cash flow · 9M-2025 | $-25M |
Risks flagged
Macroeconomic uncertainty
“We are continuing to closely monitor macroeconomic factors, including, but not limited to, continued inflationary and interest rate pressures, changes in countries’ trade policies and tariffs, challenging capital market conditions and the limited availability of financing alternatives.” · word for word
Customer concentration risk
“Device orders from a government customer are typically large orders and can be impacted by the timing of their capital budgets. As a result, the revenue for our handheld devices can vary significantly from period-to-period and has been and may continue to be concentrated in a small number of customers in any given period.” · word for word
Contingent consideration liability volatility
“The fair value of contingent consideration increased by $20.0 million during the nine months ended September 30, 2025, due to an increase in the projections for FTIR revenue, including the recent product launch of VipIR, and the increase in the Company’s publicly quoted share price.” · word for word
10 Nov 20258-K · 2.02Revenue $14M (-4% y/y); Revenue $39M (+16% y/y); Recurring revenue $5M (+10% y/y); Guidance: FY2025 revenue guidance $54M-$56M (13-17% growth)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $14M | -4% y/y |
| Revenue · 9M-2025 | $39M | +16% y/y |
| Recurring revenue · Q3-2025 | $5M | +10% y/y |
| Adjusted gross margin · Q3-2025 | 58.0% | |
| Adjusted EBITDA loss · Q3-2025 | $-2M | |
| Cash, cash equivalents and marketable securities · Q3-2025 | $112M | |
| Installed base · Q3-2025 | 3,512 | +27% y/y |
Guidance
FY2025 revenue guidance $54M-$56M (13-17% growth)
Reiterated FY2025 guidance; strong QoQ margin improvement; on track for positive adjusted EBITDA in Q4.
Risks flagged
U.S. government shutdown risk could delay awards and shipments.
“While the U.S. Government shutdown may affect the timing of certain awards and shipments, our demand outlook and strategic progress remain strong.” · word for word
Q3 revenue declined 4% YoY due to fewer mass spec device placements.
“Revenue was $14.0 million for the three months ended September 30, 2025, a 4% decrease over the prior year period, largely driven by a decrease in handheld product and service revenue resulting from fewer mass spec device placements.” · word for word
908 Devices Inc. — questions
- What did 908 Devices Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 8-K on 2026-08-11 — Revenue up 23% YoY, adjusted EBITDA loss halved, raised low end of FY revenue guidance.
Every figure on this page comes from 908 Devices Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.